Shenyang Xingqi Eye Hospital. Shenyang Xingqi Eye Hospital has suspended the prescription of 0.01% atropine sulfate eye drops, the hospital announced on July 22.
Atropine eye drops, originally a dilated optometry drug, has been found to have a certain role in preventing and controlling the progression of myopia in recent years. In October 2021, the National Health Commission issued the Appropriate Technical Guidelines for the Prevention and Control of myopia in Children and Adolescents (Updated version), which suggested the use of atropine eye drops in formal medical institutions under the guidance of doctors.
Shenyang Xingqi Eye Hospital is a wholly-owned subsidiary of Xingqi Eye Medicine co., LTD. (300573), with Internet hospital qualification and atropine sulfate eye drops. Previously, patients across the country could buy the product through the Internet hospital platform. At the end of June this year, there was market news that Internet hospitals will limit the issuance of hospital preparation atropine, causing changes in the ophthalmic sector including Xingqi Ophthalmic medicine.
At that time, a reporter from Thepaper.cn, as an investor, contacted the department of Xingqi Eye Medicine securities. A staff member said on the phone that the company had not received relevant notice and wanted to prescribe atropine eye drops and other drugs. The patient registered at the hospital through the Internet and received a doctor's diagnosis and treatment to issue relevant prescriptions.
No low-concentration atropine eye drops have been officially approved in China, and only some medical institutions have "hospital preparations". The so-called hospital preparations, also known as medical institution preparations, are fixed prescription preparations prepared by medical institutions according to the clinical needs of their own units and approved for their own use, which are not available in the market.
In addition to Xingqi Eye Hospital, there are other domestic institutions that have atropine eye drops with the nature of hospital preparations. For example, on November 18, 2021, Shandong Eye Hospital approved 0.01% atropine sulfate eye drops for market use. Aier Eye Hospital, Ho eye Hospital and other private eye hospitals also have such products.
As for whether there is compliance risk in selling hospital preparations through Internet hospital channels, the above staff said that it has not been said that this mode can not be done. A lawyer concerned with the medical field told thepaper.cn that currently, China only forbids online hospitals from prescribing narcotic drugs, psychotropic drugs and other drugs with high drug risks and other special regulations, but does not explicitly prohibit the prescribing of hospital preparations such as tropin eye drops.
The lawyer believes that if the Internet hospital is in accordance with the drug Administration Law, Internet Diagnosis and Treatment Management Measures (trial), Internet Hospital management Measures (trial) and other legal norms prescribed procedures for patients to open and mail, is not illegal. Possible legal risk mainly lies in the diagnosis and treatment compliance of the Internet problem, diagnosis and treatment process and formulation of the issue should be in accordance with the procedures prescribed by the laws and regulations, and can only be in the medical institutions by practicing doctors or assistant practicing doctors prescription, and in the "practice license of medical institution" diagnosis and treatment scope is consistent, Online hospitals are not allowed to sell preparations in disguise, otherwise they will be punished by drug regulatory authorities.
Lawyers also pointed out that the hospital preparation, after all, is not a registered drug only a complementary form of drug, even though the Internet issue of compliance, hospital drug regulatory departments should be based on the characteristics of Internet hospital, issued a lot of similar to Internet hospital preparations and related tropic eye drops for safety assessment, and relevant regulations, to regulate, Plug loopholes, in order to ensure the safety of the people's drug use.
As of press time, Xingqi eye Medicine (300573) down 0.25%.